Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: Results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]

BMC Dermatology

Volumn 5, Issue , 2005, Pages

  Ortonne, Jean Paul ^a   Shear, Neil ^b   Shumack, Stephen ^c   Henninger, Eric ^d  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b Ventana Clinical Research Corporation   (Canada)

^c St George Private Hospital   (Australia)

^d Serono International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; RETINOID; TIOGUANINE; DERMATOLOGICAL AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MYALGIA; PHASE 3 CLINICAL TRIAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RIGOR; SYMPTOM; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ADOLESCENT; HEALTH SURVEY; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HEALTH SURVEYS; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PRURITUS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 29544451927     PISSN: 14715945     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-5-13     Document Type: Article

References (33)

1. De Korte J, Sprangers MA, Mombers FM, Bos JD: Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004, 9: 140-147.
2. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE: Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997, 137: 755-760.
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001, 137: 280-284.
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999, 41: 401-407.
5. Fried RG, Friedman S, Paradis C, Hatch M, Lynfield Y, Duncanson C, Shalita A: Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995, 34: 101-105.
6. Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A: Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002, 16: 347-352.
7. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN: Suicidal ideation in psoriasis. Int J Dermatol 1993, 32: 188-190.
8. Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, De Rie MA: The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004, 9: 131-135.
9. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JG, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000, 43: 281-285.
10. Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY: Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001, 144: 967-972.
11. Rapp SR, Feldman SR: The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol Ther 2004, 17: 376-382.
12. Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46: 1-23.
13. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996, 157: 4986-4995.
14. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A; Efalizumab Study Group: Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 2003, 290: 3073-3080.
15. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D; Efalizumab Study Group: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349: 2004-2013.
16. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke P, Compton PG, Gottleib AB; Efalizumab Study Group: Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005, 52: 425-433.
17. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005, 141: 31-38.
18. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL; Efalizumab Study Group: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004, 3: 614-624.
19. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A; Efalizumab Study Group. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial. Int J Dermatol, in press.
20. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE, Jr.: Impact of efalizumab on psoriasis-speciflc patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004, 3: 27-38.
21. Ware JE, Jr., Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473-483.
22. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19: 210-216.
23. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ: Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997, 133: 1433-1440.
24. Lewis VJ, Finlay AY: A critical review of quality-of-life scales for psoriasis. Dermatol Clin 2005, 23: 707-716.
25. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA: Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health and Quality of Life Outcomes 2003, 1: 53.
26. Khilji FA, Gonzalez M, Finlay AY: Clinical meaning of change in Dermatology Life Quality Index scores. British Journal of Dermatology 2002, 147: 25-54.
27. Ware JE, Koninski M, Dewey JE. How to score version two of the SF-36 health survey. Lincoln, RI: Quality Metric Incorporated; 2000.
28. De Korte J, Mombers FM, Sprangers MA, Bos JD: The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002, 138: 1221-1227.
29. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003, 349: 658-665.
30. Gollnick HP: Oral retinoids - efficacy and toxicity in psoriasis. Br J Dermatol 1996, 135 Suppl 49: 6-17.
31. Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, Johnston A, Katsambas A, Lison AE, Naeyaert JM, Nakagawa H, Paul C, Vanaclocha F: Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004, 150 Suppl 67: 11-23.
32. Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG et al.: Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998, 134: 595-598.
33. Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M: Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998, 38: 478-485.